Risk factors for the development of glucocorticoid-induced diabetes mellitus

Takayuki Katsuyama, Kenei Sada, Sayaka Namba, Haruki Watanabe, Eri Katsuyama, Toshio Yamanari, Jun Wada, Hirofumi Makino

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM. Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors. Results: During a four-week period, 84 of the 128 patients (65.6%) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p2, p=0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0%) and lower eGFR (2) were identified as independent risk factors for GC-DM (OR 2.95, 95% CI 1.15-7.92, OR: 3.05, 95% CI 1.11-9.21, OR: 3.42, 95% CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM. Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered.

Original languageEnglish
Pages (from-to)273-279
Number of pages7
JournalDiabetes Research and Clinical Practice
Volume108
Issue number2
DOIs
Publication statusPublished - May 1 2015

Fingerprint

Glucocorticoids
Diabetes Mellitus
Multivariate Analysis
Hyperglycemia
Inpatients
Odds Ratio
Kidney
Glucose
Incidence

Keywords

  • Glucocorticoid-induced diabetes mellitus
  • Renal disease
  • Rheumatic disease
  • Risk factor

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Endocrinology
  • Medicine(all)

Cite this

Risk factors for the development of glucocorticoid-induced diabetes mellitus. / Katsuyama, Takayuki; Sada, Kenei; Namba, Sayaka; Watanabe, Haruki; Katsuyama, Eri; Yamanari, Toshio; Wada, Jun; Makino, Hirofumi.

In: Diabetes Research and Clinical Practice, Vol. 108, No. 2, 01.05.2015, p. 273-279.

Research output: Contribution to journalArticle

@article{bd72625181f148148ae653eba3c1c6e2,
title = "Risk factors for the development of glucocorticoid-induced diabetes mellitus",
abstract = "Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM. Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors. Results: During a four-week period, 84 of the 128 patients (65.6{\%}) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p2, p=0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0{\%}) and lower eGFR (2) were identified as independent risk factors for GC-DM (OR 2.95, 95{\%} CI 1.15-7.92, OR: 3.05, 95{\%} CI 1.11-9.21, OR: 3.42, 95{\%} CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM. Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered.",
keywords = "Glucocorticoid-induced diabetes mellitus, Renal disease, Rheumatic disease, Risk factor",
author = "Takayuki Katsuyama and Kenei Sada and Sayaka Namba and Haruki Watanabe and Eri Katsuyama and Toshio Yamanari and Jun Wada and Hirofumi Makino",
year = "2015",
month = "5",
day = "1",
doi = "10.1016/j.diabres.2015.02.010",
language = "English",
volume = "108",
pages = "273--279",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Risk factors for the development of glucocorticoid-induced diabetes mellitus

AU - Katsuyama, Takayuki

AU - Sada, Kenei

AU - Namba, Sayaka

AU - Watanabe, Haruki

AU - Katsuyama, Eri

AU - Yamanari, Toshio

AU - Wada, Jun

AU - Makino, Hirofumi

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM. Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors. Results: During a four-week period, 84 of the 128 patients (65.6%) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p2, p=0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0%) and lower eGFR (2) were identified as independent risk factors for GC-DM (OR 2.95, 95% CI 1.15-7.92, OR: 3.05, 95% CI 1.11-9.21, OR: 3.42, 95% CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM. Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered.

AB - Aims: To evaluate the incidence of glucocorticoid-induced diabetes mellitus (GC-DM) by repeated measurements of the postprandial glucose and detect predictors for the development of GC-DM. Methods: Inpatients with rheumatic or renal disease who received glucocorticoid therapy were enrolled in this study. We compared the clinical and laboratory parameters of the GC-DM group with the non-GC-DM group and performed a multivariate analysis to identify risk factors. Results: During a four-week period, 84 of the 128 patients (65.6%) developed GC-DM. All patients were diagnosed based on the detection of postprandial hyperglycemia. The GC-DM group had an older age (65.2 vs. 50.4 years, p2, p=0.0003) than the non-GC-DM group. According to the multivariate analysis, an older age (more than or equal to 65 years), higher HbA1c level (more than or equal to 6.0%) and lower eGFR (2) were identified as independent risk factors for GC-DM (OR 2.95, 95% CI 1.15-7.92, OR: 3.05, 95% CI 1.11-9.21, OR: 3.42, 95% CI: 1.22-10.8, respectively). The risk ratio for the development of GC-DM in the patients with at least one of these three risk factors was 2.28. The dose of glucocorticoids was not statistically related to the development of GC-DM. Conclusions: Patients with an older age, higher HbA1c level and lower eGFR require close monitoring for the development of GC-DM, regardless of the dose of glucocorticoids being administered.

KW - Glucocorticoid-induced diabetes mellitus

KW - Renal disease

KW - Rheumatic disease

KW - Risk factor

UR - http://www.scopus.com/inward/record.url?scp=84927912961&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84927912961&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2015.02.010

DO - 10.1016/j.diabres.2015.02.010

M3 - Article

C2 - 25765669

AN - SCOPUS:84927912961

VL - 108

SP - 273

EP - 279

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 2

ER -